Investigating ferroptosis in patients with SF3B1-mutant myelodysplastic syndromes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study focuses on myelodysplastic syndromes (MDS), which are blood disorders characterized by ineffective blood cell production and excessive cell death. It aims to explore the role of ferroptosis, a specific type of cell death linked to iron accumulation, in patients with SF3B1 mutations. By comparing bone marrow samples from MDS patients to those without the condition, the study seeks to determine the extent of ferroptosis activation in these patients. The methodology includes flow cytometry to analyze peroxidized lipids, which will help elucidate the pathophysiology of MDS and identify potential new therapeutic targets.

Why it matters

Who can join: the full rules

Inclusion Criteria:

For all :

* Patients of legal age (age ≥ 18 years)
* Subjects affiliated to or benefiting from a social security scheme
* Free, written and informed consent signed by the participant and the investigator

For MDS patients :

* Sampling at diagnosis for MDS patients (WHO 2016 criteria)
* Presence of ring sideroblasts on bone marrow smear

For MGUS patients :

\- Sampling as part of the exploration of monoclonal gammopathy of undetermined significance (MGUS) for controls (WHO 2016 criteria).

Exclusion Criteria:

For all

* Patient transfused with red blood cells within 120 days prior to collection
* Patients treated with haematopoietic growth factors (EPO, TPO, G-CSF) within 30 days prior to collection
* Patients with conditions that affect systemic iron metabolism: hemochromatosis, Gaucher disease, ferroportin disease, porphyria cutanea tarda
* Person under a legal protection measure (legal protection, guardianship or curatorship)
* Person deprived of liberty by judicial or administrative decision
* Person who is unable to give consent
* Subject who is in an exclusion period after another study or who has participated in another interventional drug study within 30 days prior to entry into the protocol

Where it's running

• CHU de Bordeaux, Service Hématologie Clinique et Thérapie Cellulaire
  Pessac, France Recruiting
• CHU de Bordeaux, Laboratoire d'Hématologie
  Pessac, France Not yet recruiting
• CHU de Bordeaux, Service de Médecine Interne
  Pessac, France Not yet recruiting

Study contacts

• Study coordinator: Victor-Emmanuel BRETT
• Email: victor.brett@chu-bordeaux.fr
• Phone: 0556774357

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cardiac rehab in CAD: does it affect ferroptosis?

  This study tests whether a structured cardiac rehabilitation program changes ferroptosis markers in people with coronary artery disease compared with those who don’t participate and healthy volunteers.

  Recruiting TC Erciyes University · Kayseri, Kayseri · NCT07722637

• Age-stratified conditioning regimens to improve outcomes in haploidentical stem cell transplant for myelodysplastic syndrome

  This study tests two conditioning regimens in adults with MDS undergoing haploidentical stem cell transplant to see how age affects outcomes over one year.

  Recruiting Phase 2 Peking University People's Hospital · Beijing · NCT07677306

• FXS0683 in relapsed or refractory blood cancers

  This first‑in‑human study tests FXS0683 in adults with relapsed or refractory B‑cell lymphoma, AML, MDS, or ALL to see if it is safe, how the drug behaves in the body, and whether it shows any antitumor activity.

  Recruiting Phase 1 Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Tianjin, Tianjin Municipality · NCT07616089

• Brain network changes in adults with anemia measured by fNIRS

  This project will use functional near-infrared spectroscopy (fNIRS) to see if brain network connections are altered in adults aged 18–65 who have anemia.

  Recruiting Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07578675

• Cord blood transplant for children and young adults with blood cancers.

  This study will test whether a cord blood transplant given as a first or second transplant can help children and young adults with leukemia, myelodysplasia, or lymphoma who lack a matched donor.

  Recruiting Phase 2 Memorial Sloan Kettering Cancer Center · New York, New York · NCT07566377

• Reduced-intensity donor stem cell transplant with treosulfan/fludarabine and post-transplant cyclophosphamide for leukemia and MDS

  This trial tests a lower-intensity donor stem cell transplant using treosulfan plus fludarabine with post-transplant cyclophosphamide to try to reduce toxicity and prevent graft-versus-host disease in people aged 2–75 with acute leukemias or myelodysplastic syndromes.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT07493538

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.